Comprehensive fluorogenic derivatization-liquid chromatography/tandem mass spectrometry proteomic analysis of colorectal cancer cell to identify biomarker candidate

Biomedical Chromatography

Volumn 27, Issue 4, 2013, Pages 440-450

  Koshiyama, Akiyo ^a   Ichibangase, Tomoko ^a   Imai, Kazuhiro ^a  

^a MUSASHINO UNIVERSITY   (Japan)

Author keywords

Biomarker; Colorectal cancer; FD LC MS MS; Metastasis; Proteomics

Indexed keywords

CANCER CELLS; CELL CULTURE; CELL PROLIFERATION; DIAGNOSIS; DISEASES; FINITE DIFFERENCE METHOD; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; MOLECULAR BIOLOGY; PATHOLOGY; PROTEINS; TUMORS;

COLORECTAL CANCER; COLORECTAL CANCER CELL; DERIVATIZATIONS; FD-LC-MS/MS; FLUOROGENICS; LC-MS-MS; LC.MS/MS; LIQUID CHROMATOGRAPHY/TANDEM MASS SPECTROMETRY; METASTASIS; PROTEOMICS;

BIOMARKERS;

40 S RIBOSOME PROTEIN; 60 S RIBOSOME PROTEIN; CARRIER PROTEINS AND BINDING PROTEINS; CYCLOPHILIN A; CYSTATIN B; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FATTY ACID BINDING PROTEIN 5; GALECTIN 1; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; HEAT SHOCK COGNATE PROTEIN 70; LACTATE DEHYDROGENASE; LACTATE DEHYDROGENASE B CHAIN; NUCLEAR PROTEIN; PEPTIDYLPROLYL ISOMERASE; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROTEIN 14 3 3; PROTEIN S6; RAN PROTEIN; RIBOSOMAL PROTEIN L24; RIBOSOME PROTEIN S21; RNA BINDING PROTEIN; RPS6 PROTEIN; THIOREDOXIN; TRANSFORMING GROWTH FACTOR BETA; TROPOMYOSIN 4; TUMOR MARKER; UNCLASSIFIED DRUG;

ACTIN FILAMENT; ANGIOGENESIS; ARTICLE; ASCITES FLUID; CANCER CELL CULTURE; CELL PROLIFERATION; COLON METASTASIS; COLORECTAL CANCER; CONTROLLED STUDY; DERIVATIZATION; DOWN REGULATION; ENERGY YIELD; EPITHELIAL MESENCHYMAL TRANSITION; FLUOROGENIC DERIVATIZATION; HUMAN; HUMAN CELL; HYPOXIA; LIQUID CHROMATOGRAPHY; MICROSATELLITE INSTABILITY; PROTEIN ANALYSIS; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TANDEM MASS SPECTROMETRY; TUMOR GROWTH; UPREGULATION;

EID: 84874893036     PISSN: 02693879     EISSN: 10990801     Source Type: Journal    
DOI: 10.1002/bmc.2811     Document Type: Article

References (59)

1. Ang CS, Phung J and Nice EC. The discovery and validation of colorectal cancer biomarkers. Biomedical Chromatography 2011; 25: 82-99.
2. Asamoto H, Ichibangase T, Uchikura K and Imai K. Application of an improved proteomics method, fluorogenic derivatization-liquid chromatography-tandem mass spectrometry, to differential analysis of proteins in small regions of mouse brain. Journal of Chromatography. A 2008; 1208: 147-155.
3. Azuma M, Shi M, Danenberg KD, Gardner H, Barrett C, Jacques CJ, Sherod A, Iqbal S, El-Khoueiry A, Yang D, Zhang W, Danenberg PV and Lenz HJ. Serum lactate dehydrogenase levels and glycolysis significantly correlate with tumor VEGFA and VEGFR expression in metastatic CRC patients. Pharmacogenomics 2007; 8: 1705-1713.
4. Bakin AV, Safina A, Rinehart C, Daroqui C, Darbary H and Helfman DM. A critical role of tropomyosins in TGF-beta regulation of the actin cytoskeleton and cell motility in epithelial cells. Molecular Biology of the Cell 2004; 15: 4682-4694.
5. Barkic M, Crnomarkovic S, Grabusic K, Bogetic I, Panic L, Tamarut S, Cokaric M, Jeric I, Vidak S and Volarevic S. The p53 tumor suppressor causes congenital malformations in Rpl24-deficient mice and promotes their survival. Molecular Biology of the Cell 2009; 29: 2489-2504.
6. Berggren M, Gallegos A, Gasdaska JR, Gasdaska PY, Warneke J and Powis G. Thioredoxin and thioredoxin reductase gene expression in human tumors and cell lines, and the effects of serum stimulation and hypoxia. Anticancer Research 1996; 16: 3459-3466.
7. Calvisi DF, Wang C, Ho C, Ladu S, Lee SA, Mattu S, Destefanis G, Delogu S, Zimmermann A, Ericsson J, Brozzetti S, Stanscia T, Chen X, Dombrowski F and Evert M. Increased lipogenesis, induced by AKT-mTORC1-RPS6 signaling, promotes development of human hepatocellular carcinoma. Gastroenterology 2011; 140: 1071-1083.
8. Camby I, Le Mercier M, Lefranc F and Kiss R. Galectin-1: a small protein with major functions. Glycobiology 2006; 16: 137-157.
9. Cespedes MV, Espina C, Garcia-Cabezas MA, Trias M, Boluda A, del Pulgar MTG, Sancho FJ, Nistal M, Lacal JC and Mangues R. Orthotopic microinjection of human colon cancer cells in nude mice induces tumor foci in all clinically relevant metastatic sites. The American Journal of Pathology 2007; 170: 1077-1085.
10. Colell A, Fernandez A and Fernandez-Checa JC. Mitochondria, cholesterol and amyloid beta peptide: a dangerous trio in Alzheimer disease. Journal of Bioenergetics and Biomembranes 2009; 41: 417-423.
11. Crawford NPS, Colliver DW and Galandiuk S. Tumor markers and colorectal cancer: utility in management. Journal of Surgical Oncology 2003; 84: 239-248.
12. Cuezva JM, Krajewska M, de Heredia ML, Krajewski S, Santamaria G, Kim H, Zapata JM, Marusawa H, Chamorro M and Reed JC. The bioenergetic signature of cancer: a marker of tumor progression. Cancer Research 2002; 62: 6674-6681.
13. de Noo ME, Tollenaar R, Deelder AM and Bouwman LH. Current status and prospects of clinical proteomics studies on detection of colorectal cancer: hopes and fears. World Journal of Gastroenterology 2006; 12: 6594-6601.
14. Ding SJ, Li Y, Shao XX, Zhou H, Zeng R, Tang ZY and Xia QC. Proteome analysis of hepatocellular carcinoma cell strains, MHCC97-H and MHCC97-L, with different metastasis potentials. Proteomics 2004; 4: 982-994.
15. Dworniczak B and Mirault ME. Structure and expression of a human gene coding for a 71 kd heat shock 'cognate' protein. Nucleic Acids Research 1987; 15: 5181-5197.
16. Friedman DB, Hill S, Keller JW, Merchant NB, Levy SE, Coffey RJ and Caprioli RM. Proteome analysis of human colon cancer by two-dimensional difference gel electrophoresis and mass spectrometry. Proteomics 2004; 4: 793-811.
17. Geng X, Biancone L, Dai HH, Lin JJ, Yoshizaki N, Dasgupta A, Pallone F and Das KM. Tropomyosin isoforms in intestinal mucosa: production of autoantibodies to tropomyosin isoforms in ulcerative colitis. Gastroenterology 1998; 114: 912-922.
18. He YF, Wu X, Liu XH, Yan GQ and Xu CJ. LC-MS/MS Analysis of ovarian cancer metastasis-related proteins using a nude mouse model 14-3-3 zeta as a candidate biomarker. Journal of Proteome Research 2010; 9: 6180-6190.
19. Heaton JH, Dlakic WM, Dlakic M and Gelehrter TD. Identification and cDNA cloning of a novel RNA-binding protein that interacts with the cyclic nucleotide-responsive sequence in the type-1 plasminogen activator inhibitor mRNA. Journal of Biological Chemistry 2001; 276: 3341-3347.
20. Heidtmann HH, Salge U, Abrahamson M, Bencina M, Kastelic L, Kopitar-Jerala N, Turk V and Lah TT. Cathepsin B and cysteine proteinase inhibitors in human lung cancer cell lines. Clinical & Experimental Metastasis 1997; 15: 368-381.
21. Hung KE, Faca V, Song K, Sarracino DA, Richard LG, Krastins B, Forrestor S, Porter A, Kunin A, Mahmood U, Haab BB, Hanash SM and Kucherlapati R. Comprehensive proteome analysis of an apc mouse model uncovers proteins associated with intestinal tumorigenesis. Cancer Prevention Research 2009; 2: 224-233.
22. Ichibangase T, Moriya K, Koike K and Imai K. A proteomics method revealing disease-related proteins in livers of hepatitis-infected mouse model. Journal of Proteome Research 2007; 6: 2841-2849.
23. Ichibangase T, Saimaru H, Takamura N, Kuwahara T, Koyama A, Iwatsubo T and Imai K. Proteomics of Caenorhabditis elegans over-expressing human alpha-synuclein analyzed by fluorogenic derivatization-liquid chromatography/tandem mass spectrometry: identification of actin and several ribosomal proteins as negative markers at early Parkinson's disease stages. Biomedical Chromatography 2008; 22: 232-234.
24. Ichibangase T and Imai K. Application of fluorogenic derivatization-liquid chromatography-tandem mass spectrometric proteome method to skeletal muscle proteins in fast thoroughbred horses. Journal of Proteome Research 2009; 8: 2129-2134.
25. Illemann M, Bird N, Majeed A, Laerum OD, Lund LR, Dano K and Nielsen BS. Two distinct expression patterns of urokinase, urokinase receptor and plasminogen activator inhibitor-1 in colon cancer liver metastases. International Journal of Cancer 2009; 124: 1860-1870.
26. Imai K, Ichibangase T, Saitoh R and Hoshikawa Y. A proteomics study on human breast cancer cell lines by fluorogenic derivatization-liquid chromatography/tandem mass spectrometry. Biomedical Chromatography 2008; 22: 1304-1314.
27. Kabe Y, Ando K, Hirao S, Yoshida M and Handa H. Redox regulation of NF-kappa B activation: Distinct redox regulation between the cytoplasm and the nucleus. Antioxidant Redox Signaling 2005; 7: 395-403.
28. Kannan-Thulasiraman P, Seachrist DD, Mahabeleshwar GH, Jain MK and Noy N. Fatty acid-binding protein 5 and PPAR beta/delta are critical mediators of epidermal growth factor receptor-induced carcinoma cell growth. Journal of Biological Chemistry 2010; 285: 19106-19115.
29. Kobayashi R, Deavers M, Patenia R, Rice-Stitt T, Halbe J, Gallardo S and Freedman RS. 14-3-3 Zeta protein secreted by tumor associated monocytes/macrophages from ascites of epithelial ovarian cancer patients. Cancer Immunology, Immunotherapy 2009; 58: 247-258.
30. Kos J, Krasovec M, Cimerman N, Nielsen HJ, Christensen IJ and Brunner N. Cysteine proteinase inhibitors stefin A, stefin B, and cystatin C in sera from patients with colorectal cancer: relation to prognosis. Clinical Cancer Research 2000; 6: 505-511.
31. Lee J. Role of cyclophilin A during oncogenesis. Archives of Pharmaceutical Research 2010; 33: 181-187.
32. Lin JJC, Eppinga RD, Warren KS and McCrae KR. Human tropomyosin isoforms in the regulation of cytoskeleton functions. Tropomyosin 2008; 644: 201-222.
33. Lu J, Guo H, Treekitkarnmongkol W, Li P, Zhang J, Shi B, Ling C, Zhou X, Chen T, Chiao PJ, Feng X, Seewaldt VL, Muller WJ, Sahin A, Hung MC and Yu D. 14-3-3ζ Cooperates with ErbB2 to promote ductal carcinoma in situ progression to invasive breast cancer by inducing epithelial-mesenchymal transition. Cancer Cell 2009; 16: 195-207.
34. Massey AJ, Williamson DS, Browne H, Murray JB, Dokurno P, Shaw T, Macias AT, Daniels Z, Geoffroy S, Dopson M, Lavan P, Matassova N, Francis GL, Graham CJ, Parsons R, Wang Y, Padfield A, Comer M, Drysdale MJ and Wood M. A novel, small molecule inhibitor of Hsc70/Hsp70 potentiates Hsp90 inhibitor induced apoptosis in HCT116 colon carcinoma cells. Cancer Chemotherapy and Pharmacology 2010; 66: 535-545.
35. Masuda M, Toriumi C, Santa T and Imai K. Fluorogenic derivatization reagents suitable for isolation and identification of cysteine-containing proteins utilizing high-performance liquid chromatography-tandem mass spectrometry. Analytical Chemistry 2004; 76: 728-735.
36. Morgan E, Kannan-Thulasiraman P and Noy N. Involvement of fatty acid binding protein 5 and PPAR beta/delta in prostate cancer cell growth. PPAR Research 2010; 1-9.
37. Muslin AJ, Tanner JW, Allen PM and Shaw AS. Interaction of 14-3-3 with signaling proteins is mediated by the recognition of phosphoserine. Cell 1996; 84: 889-897.
38. Neal CL, Yao J, Yang WT, Zhou XY, Nguyen NT, Lu J, Danes CG, Guo H, Lan KH, Ensor J, Hittelman W, Hung MC and Yu D. 14-3-3 Zeta overexpression defines high risk for breast cancer recurrence and promotes cancer cell survival. Cancer Research 2009; 69: 3425-3432.
39. Obchoei S, Wongkhan S, Wongkham C, Li M, Yao QZ and Chen CY. Cyclophilin A: potential functions and therapeutic target for human cancer. Medical Science Monitor 2009; 15: RA221-232.
40. O'Dwyer D, Ralton LD, O'Shea A and Murray GI. The proteomics of colorectal cancer: identification of a protein signature associated with prognosis. PLoS One 2011; 6(11): e27718; doi: 10.1371.
41. Ohyama K, Tomonari M, Ichibangase T, To H, Kishikawa N, Nakashima K, Imai K and Kuroda N. A toxicoproteomic study on cardioprotective effects of pre-administration of docetaxel in a mouse model of adriamycin-induced cardiotoxicity. Biochemical Pharmacology 2010; 80: 540-547.
42. Park JE, Sen Tan H, Datta A, Lai RC, Zhang HM, Meng W, Lim SK and Sze SK. Hypoxic tumor cell modulates its microenvironment to enhance angiogenic and metastatic potential by secretion of proteins and exosomes. Molecular & Cellular Proteomics 2010; 9: 1085-1099.
43. Petrova DT, Asif AR, Armstrong VW, Dimova I, Toshev S, Yaramov N, Oellerich M and Toncheva D. Expression of chloride intracellular channel protein 1 (CLIC1) and tumor protein D52 (TPD52) as potential biomarkers for colorectal cancer. Clinical Biochemistry 2008; 41: 1224-1236.
44. Pino MS, Kikuchi H, Zeng M, Herraiz MT, Sperduti I, Berger D, Park DY, Iafrate AJ, Zukerberg LR and Chung DC. Epithelial to mesenchymal transition is impaired in colon cancer cells with microsatellite instability. Gastroenterology 2010; 138: 1406-1417.
45. Pohl M, Stricker I, Schoeneck A, Schulmann K, Klein-Scory S, Schwarte-Waldhoff I, Hasmann M, Tannapfel A, Schmiegel W and Reinacher-Schick A. Antitumor activity of the HER2 dimerization inhibitor pertuzumab on human colon cancer cells in vitro and in vivo. Journal of Cancer Research and Clinical Oncology 2009; 135: 1377-1386.
46. Quimby BB and Dasso M. The small GTPase Ran: interpreting the signs. Current Opinion in Cell Biology 2003; 15: 338-344.
47. Rabinovich GA, Ramhorst RE, Rubinstein N, Corigliano A, Daroqui MC, Kier-Joffe EB and Fainboim L. Induction of allogenic T-cell hyporesponsiveness by galectin-1-mediated apoptotic and non-apoptotic mechanisms. Cell Death and Differentiation 2002; 9: 661-670.
48. Raffel J, Bhattacharyya AK, Gallegos A, Cui HY, Einspahr JG, Alberts DS and Powis G. Increased expression of thioredoxin-1 in human colorectal cancer is associated with decreased patient survival. The Journal of Laboratory and Clinical Medicine 2003; 142: 46-51.
49. Rivenbark AG and Coleman WB. Epigenetic regulation of cystatins in cancer. Frontiers in Bioscience 2009; 14: 453-462.
50. Roudier E and Perrin A. Considering the role of pyruvate in tumor cells during hypoxia. Biochimica et Biophysica Acta 2009; 1796: 55-62.
51. Semenza GL, Jiang BH, Leung SW, Passantino R, Concordet JP, Maire P and Giallongo A. Hypoxia response elements in the aldolase A, enolase 1, and lactate dehydrogenase A gene promoters contain essential binding sites for hypoxia-inducible factor 1. Journal of Biological Chemistry 1996; 271: 32529-32537.
52. Shawler DL, Bartholomew RM, Garrett MA, Trauger RJ, Dorigo O, Van Beveren C, Marchese A, Ferre F, Duffy C, Carlo DJ, Sherman LA, Gold DP and Sobol RE. Antigenic and immunologic characterization of an allogeneic colon carcinoma vaccine. Clinical and Experimental Immunology 2002; 129: 99-106.
53. Thangaraju M, Carswell KN, Prasad PD and Ganapathy V. Colon cancer cells maintain low levels of pyruvate to avoid cell death caused by inhibition of HDAC1/HDAC3. Biochemical Journal 2009; 417: 379-389.
54. Wind T, Hansen M, Jensen JK and Andreasen PA. The molecular basis for anti-proteolytic and non-proteolytic functions of plasminogen activator inhibitor type-1: Roles of the reactive centre loop, the shutter region, the flexible joint region and the small serpin fragment. Biological Chemistry 2002; 383: 21-36.
55. Yamauchi T, Watanabe M, Hasegawa H, Nishibori H, Ishii Y, Tatematsu H, Yamamoto K, Kubota T and Kitajima M. The potential for a selective cyclooxygenase-2 inhibitor in the prevention of liver metastasis in human colorectal cancer. Anticancer Research 2003; 23: 245-249.
56. Yang H, Chen J, Yang J, Qiao S, Zhao S and Yu L. Cyclophilin A is upregulated in small cell lung cancer and activates ERK1/2 signal. Biochemical and Biophysical Research Communications 2007; 361: 763-767.
57. Yokota S, Yamamoto Y, Shimizu K, Momoi H, Kamikawa T, Yamaoka Y, Yanagi H, Yura T and Kobota H. Increased expression of cytosolic chaperonin CCT in human hepatocellular and colonic carcinoma. Cell Stress & Chaperones 2001; 6: 345-350.
58. Zha XJ, Wang F, Wang Y, He SZ, Jing YL, Wu XY and Zhang HB. Lactate dehydrogenase B is critical for hyperactive mTOR-mediated tumorigenesis. Cancer Research 2011; 71: 13-18.
59. Zhao L, Liu L, Wang S, Zhang YF, Yu L and Ding YQ. Differential proteomic analysis of human colorectal carcinoma cell lines metastasis-associated proteins. Journal of Cancer Research and Clinical Oncology 2007; 133: 771-782.